ArticleTranslational cancer research2020
LAMP1 is more sensitive than LAMP2 in predicting prognosis of esophageal squamous cell carcinoma.
Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
- Article
- Implication of LAMP proteins and autophagy markers in colorectal cancer aggressiveness.Frontiers in immunology · 2025Article
- A spatiotemporal comparative analysis on tumor immune microenvironment characteristics between neoadjuvant chemotherapy and preoperative immunotherapy for ESCC.Cell death & disease · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEsophageal squamous cell carcinoma (ESCC) is one of the most common cancers, especially in China. Its 5-year survival rate remains very low. Lysosomal associated membrane proteins (LAMPs), including LAMP1 and LAMP2, are major protein components of the lysosome, which also plays an important role in tumor evolution. Our previous studies have confirmed that LAMP1 and LAMP2 play an important role in the evolution and prognosis of ESCC. To further explore their roles in ESCC, we compared the roles of LAMP1 and LAMP2 in predicting the prognosis of ESCC.
methodsFive hundred and seventy-nine ESCC patients were enrolled in this study. The clinical information, address and telephone number of patients were collected from the medical records.
resultsThe 3-year survival rate was 51.91% (231/445), and 5-year survival rate was 34.58% (83/240). Kaplan-Meier survival curves indicated that the higher the expression level of LAMP1, the worse the prognosis of patients, compared with LAMP2 (P<0.05). Additionally, we used the receiver operating characteristic (ROC) curves to compare the sensitivity and specificity of LAMP1 and LAMP2 in predicting prognosis of ESCC. The area under the curve (AUC) of LAMP1 was significantly higher than that of LAMP2 (AUC
conclusionsLAMP1 is more sensitive than LAMP2 in predicting the prognosis of ESCC, which indicated that LAMP1 may play a more important role in the evolution and metastasis of ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.